Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Certepetide with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT05042128Phase 2Active, not recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Apr 2022
- Primary completion
- Jun 2025
- Modality
- Cyclic Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of certepetide in pancreatic ductal adenocarcinoma (PDAC), sponsored by Australasian Gastro-Intestinal Trials Group. Started Apr 2022; status: active, not recruiting.
02
Drugs
certepetide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05042128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042128.